NK1 receptor antagonists under investigation for the treatment of affective disorders

Expert Opinion on Investigational Drugs
Boldizsár CzéhMária Simon

Abstract

Substance P-neurokinin-1 (NK1) receptor pathways have been repeatedly implicated in the pathophysiology of affective disorders. Anatomical studies in humans have shown a high expression of NK1 receptors in brain regions that are important for the regulation of affective behaviours and stress responses. A large body of evidence that has been generated from animal experiments indicates that treatment with a selective NK1 receptor antagonist might be effective in the treatment of certain forms of anxiety and depressive disorders. Accordingly, numerous NK1 receptor antagonists have either been synthesised and are under clinical development, or have already been tested in clinical trials. However, the initial encouraging clinical results were followed by repeated demonstrations of a lack of effectiveness, thus disappointment and doubt currently surrounds the idea that these compounds may become effective antidepressants. Research continues and novel molecules may show better pharmacokinetic and pharmacodynamic properties and, therefore, may achieve therapeutic success. Furthermore, NK1 receptor antagonists that are ineffective in the treatment of mood disorders may still prove to be effective in the treatment of anxiety problems.

References

Jul 21, 1971·Nature: New Biology·M M ChangH D Niall
Jul 5, 1996·Regulatory Peptides·G Q ChangS A Simon
May 8, 1999·Science·M Enserink
Feb 12, 2000·Trends in Pharmacological Sciences·N M Rupniak, M S Kramer
Feb 15, 2001·Proceedings of the National Academy of Sciences of the United States of America·L SantarelliM J Heath
Mar 17, 2001·Nature Reviews. Neuroscience·C G Gross
May 1, 2001·Nature Medicine·H K ManjiD S Charney
Oct 25, 2001·Proceedings of the National Academy of Sciences of the United States of America·B CzéhE Fuchs
Aug 2, 2002·Neuroreport·Craig A StockmeierGrazyna Rajkowska
Nov 16, 2002·Progress in Brain Research·Amelia J Eisch
Dec 5, 2002·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Klaus LiebUlrich Voderholzer
Mar 20, 2003·Biological Psychiatry·Brigitta BondyHans J ürgen Möller
Jun 26, 2003·The European Journal of Neuroscience·R Ogier, M Raggenbass
Jul 3, 2003·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Jessica E Malberg, Ronald S Duman
Nov 19, 2003·The European Journal of Neuroscience·Sara MorcuendeStephen P Hunt
Dec 4, 2003·Expert Opinion on Pharmacotherapy·Lisa Patel, Celeste Lindley
Dec 11, 2003·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Mark S KramerYih Lee
Apr 2, 2004·The American Journal of Psychiatry·Stephanie CampbellGlenda M MacQueen
May 18, 2004·European Journal of Pharmacology·Denis J DavidLaurence Lanfumey
Jul 24, 2004·Biological Psychiatry·Ronald S Duman
Jul 24, 2004·Biological Psychiatry·Fritz A Henn, Barbara Vollmayr
Oct 8, 2004·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Boldizsár CzehEberhard Fuchs
Nov 27, 2004·Molecular Imaging and Biology : MIB : the Official Publication of the Academy of Molecular Imaging·Olof SolinH Donald Burns
May 17, 2005·Current Pharmaceutical Design·S McLean
Jul 2, 2005·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Klaus LiebThomas J Feuerstein

❮ Previous
Next ❯

Citations

Dec 27, 2008·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Mark J Millan
Oct 3, 2008·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Alain GobertMark J Millan
Dec 14, 2011·Current Opinion in Psychiatry·Jozsef Haller, Mano Alicki
May 1, 2012·TheScientificWorldJournal·Marisa RossoMichael Berger
Oct 18, 2011·Expert Opinion on Emerging Drugs·Giampaolo PernaDaniela Caldirola
May 21, 2010·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Mark J MillanGuillaume de Nanteuil
Feb 12, 2014·Behavioural Brain Research·Filipe Silveira DuarteThereza Christina Monteiro De Lima
May 1, 2015·Critical Care : the Official Journal of the Critical Care Forum·Leonardo LorenteAlejandro Jiménez
Sep 18, 2012·Neuroscience and Biobehavioral Reviews·J HallerK Gyimesine Pelczer
Feb 16, 2011·The International Journal of Neuropsychopharmacology·Stefano GaburroNicolas Singewald
Aug 11, 2016·Drug Discovery Today·Priya BawaViness Pillay
Dec 17, 2008·Annals of the New York Academy of Sciences·Steven D DouglasLaurie E Kilpatrick
Feb 7, 2021·Drug and Alcohol Dependence·Leon FonvilleAnne Lingford-Hughes
Jul 29, 2008·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Mauricette BroccoMark J Millan

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.